Date: 2014-09-16
Type of information: Private placement
Company: Nordic Nanovector (Norway)
Investors: HealthCap, existing shareholders, new institutional and professional investors
Amount: NOK 50 million ($7,8 million - €6 million)
Funding type: private placement
Planned used: The net proceeds from the private placement will be used to finance the further development of Betalutin™ for treatment of non-Hodgkin Lymphoma.
Others: * On October 28, 2014, 5,000 share options were exercised at a strike price of NOK 6,75 per share under the Company’s share option program. After this option exercise, the total number of options outstanding is 1,080,239. The share capital increase relating to the issuance of the 5,000 shares has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 5,298,608.2 divided into 26,493,041 shares, each with a nominal value of NOK 0.2. * On October 24, 2014, HealthCap VI L.P has pursuant to the subscription agreement entered into on 26 September 2013 between Nordic Nanovector, HealthCap VI L.P. and certain shareholders of the Company subscribed for 1,666,666 new shares at a subscription price of NOK 15 per share (MNOK 25 in total) (USD 3.9). The share capital increase related to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 5,297,608.2 divided into 26,488,041 shares, each with a nominal value of NOK 0.2. * On September 22, 2014, Nordic Nanovector announced the final result of its subsequent repair offering. The share capital increase related to the issuance of the new shares in connection with the Offering has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 4,964,275 divided into 24,821,375 shares, each with a nominal value of NOK 0.2. The new shares can from now on be traded on the NOTC. * On September 16, 2014, Nordic Nanovector announced the final result of its offering of up to 2,000,000 new shares at a subscription price of NOK 25 per share. The offering was oversubscribed by approximately 35%. The final allocation of the new shares offered in the Offering has taken place today in accordance with the allocation criteria set out in the resolutions made by the general meeting of the Company held on 27 June 2014 (see the prospectus dated 28 August 2014). A total of 2,000,000 new shares have been allocated. Gross proceeds from the Offering will be NOK 50 million ($7,8 million - €6 million). The new shares have only been allocated to Eligible Shareholders (as defined in the prospectus dated 28 August 2014). Notifications of allocated new shares and the corresponding subscription amount to be paid by each Eligible Shareholder are expected to be distributed today. Payment for the allocated new shares falls due on 18 September 2014. The new shares may not be transferred or traded before they are fully paid and the share capital increase pertaining to the Offering has been registered with the Norwegian Register of Business Enterprises, expected to take place on or about 22 September 2014. ABG Sundal Collier and DNB Markets acted as managers for the Offering. * On September 15, 2014, Nordic Nanovector announced that the subscription period for the subsequent repair offering of up to 2,000,000 new shares at a subscription price of NOK 25 per share, ended on 12 September 2014 at 16:00 CET.The Offering was oversubscribed. * On August 29 2014, Nordic Nanovector announced that the Norwegian Financial Supervisory Authority (Nw. Finanstilsynet) has approved the prospectus of the Nordic Nanovector dated 28 August 2014, for the offering of up to 2,000,000 subsequent offering shares with subscription rights for eligible shareholders as of 27 June 2014 at a subscription price of NOK 25 per subsequent offering share.
Therapeutic area: Cancer - Oncology
